Researchers have completed a clinical trial suggesting that the antidepressant drug fluvoxamine may help prevent deterioration in COVID-19 patients, making hospitalization less likely.
Researchers have completed a clinical trial suggesting that the antidepressant drug fluvoxamine may help prevent deterioration in COVID-19 patients, making hospitalization less likely.